Form 4: Dianthus Therapeutics Director Sells Shares

Dianthus Therapeutics Director Paula Soteropoulos reported a transaction involving the sale of 599 shares of common stock on May 8, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Paula Soteropoulos, a Director at Dianthus Therapeutics, Inc., reported a sale of 599 shares of common stock on May 8, 2026.
• The transaction was executed at a price of $85.47 per share.
• This sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.
• The filing also notes a stock option award with an exercise price of $8.44, with 599 shares underlying the option, set to expire on June 6, 2032.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction executed under a pre-established trading plan, without immediate implications for the company's financial performance or strategic direction.

Negatives

• Director Paula Soteropoulos sold 599 shares of common stock for $85.47 per share.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan indicates pre-planned trading activity, often used by executives to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may note the sale by a director, but the execution under a Rule 10b5-1 plan suggests it was pre-planned and not necessarily a reflection of negative sentiment towards the company's future prospects.

Key Dates

Keywords

Dianthus Therapeutics, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Paula Soteropoulos, Common Stock, Stock Option